CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $177.71M, lower than 95% of all stocks globally
- PositionReturn on equity is -1207.5%, lower than 95% of its Biotechnology peers (median -21.7%)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
177.71MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.6940xvs all stocks
52-Week Change
-39.27%vs all stocks
Market Capitalization
177.71MUSDvs all stocks (USD)
Enterprise Value
85.97MUSDvs all stocks (USD)
Forward P/E
-5.28xvs Biotechnology peers
Price to Book (MRQ)
33.42xvs Biotechnology peers
Enterprise to EBITDA
-4.55xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-90.75%vs Biotechnology peers
Return on Equity (TTM)
-1207.46%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-18.89MUSDvs all stocks (USD)
Net Income (TTM)
-29.80MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-16.79MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-9.76MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00CADFY2025 · Dec 31, 2025Operating Income
-25.08MCAD-17.99M · vs all stocks (USD)
Pre-tax Income
-44.12MCADFY2025 · Dec 31, 2025Net Income
-44.12MCADFY2025 · Dec 31, 2025EBIT
-25.08MCADFY2025 · Dec 31, 2025EBITDA (Income Statement)
-5.65MCADFY2025 · Dec 31, 2025Research & Development
13.91MCADFY2025 · Dec 31, 2025Selling, General & Administrative
11.17MCADFY2025 · Dec 31, 2025Non-operating Interest Income
333.42KCADFY2025 · Dec 31, 2025Net Income from Continuing Operations
-44.12MCADFY2025 · Dec 31, 2025Operating Cash Flow
-38.33MCADFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
22.07MCADFY2025 · Dec 31, 2025Interest Paid
0.00CADFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-44.12MCADFY2025 · Dec 31, 2025Depreciation & Amortization
55.80KCADFY2025 · Dec 31, 2025Stock-based Compensation
5.39MCADFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
334.48KCADFY2025 · Dec 31, 2025Net Intangibles (CF)
100.93KCADFY2025 · Dec 31, 2025Long-term Debt Payments
-100.93KCADFY2025 · Dec 31, 2025Other Financing Charges
-892.78KCADFY2025 · Dec 31, 2025Net Financing Cash Flow
15.89MCADFY2025 · Dec 31, 2025Shares Outstanding
106.41MSharesUpdated Jul 19, 2026Float Shares
72.80MSharesUpdated Jul 19, 2026Shares Short
3.45MSharesUpdated Jul 19, 2026Short Ratio
4.49daysvs all stocks
% Held by Insiders
20.33%vs all stocks
% Held by Institutions
2.07%vs all stocks
Total Cash (MRQ)
11.79MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.2010USDUpdated Jul 19, 2026Total Debt (MRQ)
8.37KUSDvs all stocks (USD)
Current Ratio (MRQ)
1.34xvs Biotechnology peers
Book Value per Share (MRQ)
0.0500USDUpdated Jul 19, 2026Total Assets
23.21MCAD16.65M · vs all stocks (USD)
Total Current Assets
22.80MCADFY2025 · Dec 31, 2025Total Liabilities
19.73MCADFY2025 · Dec 31, 2025Total Non-current Assets
409.16KCADFY2025 · Dec 31, 2025Total Non-current Liabilities
0.00CADFY2025 · Dec 31, 2025Total Current Liabilities
19.73MCADFY2025 · Dec 31, 2025Cash & Cash Equivalents
22.07MCADFY2025 · Dec 31, 2025Other Short-term Investments
8.37KCADFY2025 · Dec 31, 2025Short-term Debt
8.37KCADFY2025 · Dec 31, 2025Other Current Liabilities
15.07MCADFY2025 · Dec 31, 2025Long-term Debt
0.00CADFY2025 · Dec 31, 2025Common Stock (Book)
103.00MCADFY2025 · Dec 31, 2025Retained Earnings
-146.76MCADFY2025 · Dec 31, 2025Total Shareholders' Equity
3.48MCAD2.49M · vs all stocks (USD)
52-Week Low
1.59USDUpdated Jul 19, 202652-Week High
6.30USDUpdated Jul 19, 202652-Week Change
-39.27%vs all stocks
Beta
0.6940xvs all stocks
50-Day MA
2.38USDUpdated Jul 19, 2026200-Day MA
3.54USDUpdated Jul 19, 2026Avg 10-Day Volume
984.70KSharesUpdated Jul 19, 2026Avg 30-Day Volume
903.54KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-0.4500USDUpdated Jul 19, 2026Other Income / Expense
-19.37MCADFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -1207.5%, lower than 95% of its Biotechnology peers (median -21.7%)Significant
Return on equity: -12.07Industry median: -0.22Industry P5: -1.66Peers compared: 261
Return on assets is -90.8%, lower than 95% of its Biotechnology peers (median -20.1%)Significant
Return on assets: -0.91Industry median: -0.20Industry P5: -0.85Peers compared: 261
Price-to-book is 33.42×, higher than 95% of its Biotechnology peers (median 2.97×)Significant
Price-to-book: 33.42Industry median: 2.97Industry P95: 23.50Peers compared: 261
Financial Health
Altman Z-Score -4.81: distress zoneCritical
Altman Z-Score: -4.81
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $177.71M, lower than 95% of all stocks globallySignificant
Market cap (USD): 177,709,097Global P5: 269,387,740.27
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
MediWound Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
ADC Therapeutics S.A.
Tier 1ProductionApproval-Gated PipelineRule
Cabio Biotech Wuhan Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Asterasys Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Anika Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Rightongene Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tonix Pharmaceuticals Holding Corp.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Voyager Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Onward Medical
Tier 1ProductionApproval-Gated PipelineRule
Camp4 Therapeutics Corp.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Regencell Bioscience Holdings Ltd.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown
ThredUp Inc.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown
T1 Energy Inc.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown